P53 alterations in bladder tumors from arsenic and tobacco exposed patients
Previous studies demonstrated that tobacco and arsenic exposure are risk factors for bladder cancer. A case-case study was conducted to compare p53 mutations in 147 bladder tumors from South American patients by tobacco and arsenic exposure. Information on residential history and lifestyle factors w...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Artículo acceptedVersion |
| Lenguaje: | Español |
| Publicado: |
2003
|
| Materias: | |
| Acceso en línea: | http://pa.bibdigital.ucc.edu.ar/3955/1/A_Moore_Smith_Eng_DeVries_Kalman_Bhargava_Chew_Ferreccio_Rey_Hopenhayn_Biggs_Bates_Waldman.pdf |
| Aporte de: |
| id |
I38-R144-3955 |
|---|---|
| record_format |
dspace |
| institution |
Universidad Católica de Córdoba |
| institution_str |
I-38 |
| repository_str |
R-144 |
| collection |
Producción Académica Universidad Católica de Córdoba (UCCor) |
| language |
Español |
| orig_language_str_mv |
spa |
| topic |
R Medicina (General) |
| spellingShingle |
R Medicina (General) Moore, Lee E. Smith, Allan H. Eng, Clarence Devries, Sandy Kalman, Dave Bhargava, Vivek Chew, Karen Ferreccio, Catterina Rey, Omar A. Hopenhayn, Claudia Biggs, Mary Lou Bates, Michael N. P53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| topic_facet |
R Medicina (General) |
| description |
Previous studies demonstrated that tobacco and arsenic exposure are risk factors for bladder cancer. A case-case study was conducted to compare p53 mutations in 147 bladder tumors from South American patients by tobacco and arsenic exposure. Information on residential history and lifestyle factors was collected. The prevalence of p53 mutations and protein expression was examined in relation to tumor stage, grade, patient age, gender, tobacco and arsenic exposure. Smokers were grouped as ever/never smokers and by pack years of exposure (0, 1-20, >20). Patients were also grouped into four arsenic exposure categories based on the average of the five highest years arsenic concentration in their drinking water: group 1, non-detectable to < 10 μg/l (n = 50); group 2, 10-99 μg/l (n = 31); group 3, 100-299 μg/l (n = 35); group 4, >300 μg/l (n = 30). The proportion of tumor samples with p53 mutations and P53 immunopositivity increased strongly with both stage and grade, but not with arsenic exposure or smoking. The prevalence of tumors containing mutational transitions increased markedly with tumor stage (from 14 to 52%, Ptrend = 0.005) and grade (from 11 to 48%, Ptrend = 0.004) and was higher in smokers than in non-smokers (34 versus 18%, respectively, P = 0.10). An increasing trend was observed with pack years of smoking (P = 0.09). The majority of mutations in tumors from both smokers and non-smokers were G → A transitions, however, in smokers a preference for G → A transitions at CpG sites was observed (P = 0.07, two-tailed) and a positive trend was observed with pack years of exposure (P = 0.04). A hotspot was found at codon 273 in 12% of the tumors from smokers but was not observed in never smokers (P = 0.05) and a positive trend was observed with pack years of tobacco exposure (P = 0.001). Neither stage nor grade demonstrated a preference for CpG site mutation, suggesting that these changes may be early exposure-related events in carcinogenesis and are not related to tumor progression. Arsenic exposure was not associated with an increased prevalence of p53 mutation or P53 immunopositivity and there was no evidence of interaction between arsenic and smoking with these outcome variables. |
| format |
Artículo Artículo acceptedVersion |
| author |
Moore, Lee E. Smith, Allan H. Eng, Clarence Devries, Sandy Kalman, Dave Bhargava, Vivek Chew, Karen Ferreccio, Catterina Rey, Omar A. Hopenhayn, Claudia Biggs, Mary Lou Bates, Michael N. |
| author_facet |
Moore, Lee E. Smith, Allan H. Eng, Clarence Devries, Sandy Kalman, Dave Bhargava, Vivek Chew, Karen Ferreccio, Catterina Rey, Omar A. Hopenhayn, Claudia Biggs, Mary Lou Bates, Michael N. |
| author_sort |
Moore, Lee E. |
| title |
P53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| title_short |
P53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| title_full |
P53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| title_fullStr |
P53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| title_full_unstemmed |
P53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| title_sort |
p53 alterations in bladder tumors from arsenic and tobacco exposed patients |
| publishDate |
2003 |
| url |
http://pa.bibdigital.ucc.edu.ar/3955/1/A_Moore_Smith_Eng_DeVries_Kalman_Bhargava_Chew_Ferreccio_Rey_Hopenhayn_Biggs_Bates_Waldman.pdf |
| work_keys_str_mv |
AT mooreleee p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT smithallanh p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT engclarence p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT devriessandy p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT kalmandave p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT bhargavavivek p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT chewkaren p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT ferrecciocatterina p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT reyomara p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT hopenhaynclaudia p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT biggsmarylou p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients AT batesmichaeln p53alterationsinbladdertumorsfromarsenicandtobaccoexposedpatients |
| _version_ |
1832592410892304384 |
| spelling |
I38-R144-39552023-07-24T17:32:32Z http://pa.bibdigital.ucc.edu.ar/3955/ P53 alterations in bladder tumors from arsenic and tobacco exposed patients Moore, Lee E. Smith, Allan H. Eng, Clarence Devries, Sandy Kalman, Dave Bhargava, Vivek Chew, Karen Ferreccio, Catterina Rey, Omar A. Hopenhayn, Claudia Biggs, Mary Lou Bates, Michael N. R Medicina (General) Previous studies demonstrated that tobacco and arsenic exposure are risk factors for bladder cancer. A case-case study was conducted to compare p53 mutations in 147 bladder tumors from South American patients by tobacco and arsenic exposure. Information on residential history and lifestyle factors was collected. The prevalence of p53 mutations and protein expression was examined in relation to tumor stage, grade, patient age, gender, tobacco and arsenic exposure. Smokers were grouped as ever/never smokers and by pack years of exposure (0, 1-20, >20). Patients were also grouped into four arsenic exposure categories based on the average of the five highest years arsenic concentration in their drinking water: group 1, non-detectable to < 10 μg/l (n = 50); group 2, 10-99 μg/l (n = 31); group 3, 100-299 μg/l (n = 35); group 4, >300 μg/l (n = 30). The proportion of tumor samples with p53 mutations and P53 immunopositivity increased strongly with both stage and grade, but not with arsenic exposure or smoking. The prevalence of tumors containing mutational transitions increased markedly with tumor stage (from 14 to 52%, Ptrend = 0.005) and grade (from 11 to 48%, Ptrend = 0.004) and was higher in smokers than in non-smokers (34 versus 18%, respectively, P = 0.10). An increasing trend was observed with pack years of smoking (P = 0.09). The majority of mutations in tumors from both smokers and non-smokers were G → A transitions, however, in smokers a preference for G → A transitions at CpG sites was observed (P = 0.07, two-tailed) and a positive trend was observed with pack years of exposure (P = 0.04). A hotspot was found at codon 273 in 12% of the tumors from smokers but was not observed in never smokers (P = 0.05) and a positive trend was observed with pack years of tobacco exposure (P = 0.001). Neither stage nor grade demonstrated a preference for CpG site mutation, suggesting that these changes may be early exposure-related events in carcinogenesis and are not related to tumor progression. Arsenic exposure was not associated with an increased prevalence of p53 mutation or P53 immunopositivity and there was no evidence of interaction between arsenic and smoking with these outcome variables. 2003-12-31 application/pdf spa http://pa.bibdigital.ucc.edu.ar/3955/1/A_Moore_Smith_Eng_DeVries_Kalman_Bhargava_Chew_Ferreccio_Rey_Hopenhayn_Biggs_Bates_Waldman.pdf Moore, Lee E., Smith, Allan H., Eng, Clarence, Devries, Sandy, Kalman, Dave, Bhargava, Vivek, Chew, Karen, Ferreccio, Catterina ORCID: https://orcid.org/0000-0001-6331-5534 <https://orcid.org/0000-0001-6331-5534>, Rey, Omar A. ORCID: https://orcid.org/0000-0002-9232-1252 <https://orcid.org/0000-0002-9232-1252>, Hopenhayn, Claudia, Biggs, Mary Lou and Bates, Michael N. (2003) P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis, 24 (11). 1785 -1791. ISSN 0143-3334 info:eu-repo/semantics/altIdentifier/doi/10.1093/carcin/bgg136 info:eu-repo/semantics/article info:ar-repo/semantics/artículo info:eu-repo/semantics/acceptedVersion Fil: Moore, Lee E. University of California, San Francisco Cancer Center, San Francisco, CA, United States Fil: Smith, Allan H. University of Washington, Seattle, WA, United States Fil: Eng, Clarence. University of California, San Francisco Cancer Center, San Francisco, CA, United States Fil: Devries, Sandy. University of California, San Francisco Cancer Center, San Francisco, CA, United States Fil: Kalman, Dave. University of Washington, Seattle, WA, United States Fil: Bhargava, Vivek. University of California, San Francisco Cancer Center, San Francisco, CA, United States Fil: Chew, Karen. University of California, San Francisco Cancer Center, San Francisco, CA, United States Fil: Ferreccio, Catterina. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentina Fil: Rey, Omar A. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentina Fil: Hopenhayn, Claudia. University of Kentucky, Lexington, KY, United States Fil: Biggs, Mary Lou. University of Washington, Seattle, WA, United States Fil: Bates, Michael N. Arsenic Health Research Program, School of Public Health, University of California, Berkeley, CA 7360, 140 Warren Hall, United States info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |